Research Agreements (Details)	3 Months Ended		6 Months Ended						1 Months Ended				3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended	1 Months Ended			6 Months Ended						1 Months Ended	6 Months Ended				0 Months Ended				6 Months Ended						1 Months Ended			6 Months Ended
	Jun. 30, 2013 USD ($)	Jun. 30, 2012 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2012 USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Maximum USD ($) item	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Maximum EUR (€)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Nordic USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-TD Phase 2 Clinical Study Nordic USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement BA058-TD Phase 2 Clinical Study Nordic Maximum USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement BA058-TD Phase 2 Clinical Study Nordic Maximum EUR (€)	Feb. 28, 2013 Clinical Trial Services Agreement BA058-TD Phase 2 Clinical Study Nordic Series A-6 Maximum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Extension Clinical Study Nordic USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Pass-through costs USD ($)	Jun. 30, 2012 Clinical Trial Services Agreement Pass-through costs USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Pass-through costs USD ($)	Jun. 30, 2012 Clinical Trial Services Agreement Pass-through costs USD ($)	Dec. 31, 2011 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study item	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2012 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2012 Clinical Trial Services Agreement BA058-SC Phase 3 Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-TD Phase 2 Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Extension Clinical Study Nordic Maximum USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement BA058-SC Phase 3 Extension Clinical Study Nordic Maximum EUR (€)	Dec. 31, 2011 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study item	Jun. 30, 2013 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study United States item	Jun. 30, 2013 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study United States Maximum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study United States Maximum EUR (€)	Jun. 30, 2013 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study India item	Jun. 30, 2013 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study India Maximum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement First Amendment BA058-SC Phase 3 Clinical Study India Maximum EUR (€)	Jun. 30, 2012 Clinical Trial Services Agreement Second Amendment BA058-SC Phase 3 Clinical Study item	Jun. 30, 2013 Clinical Trial Services Agreement Second Amendment BA058-SC Phase 3 Clinical Study USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Second Amendment BA058-SC Phase 3 Clinical Study EUR (€)	Jun. 30, 2013 Clinical Trial Services Agreement Second Amendment BA058-SC Phase 3 Clinical Study Maximum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Second Amendment BA058-SC Phase 3 Clinical Study Maximum EUR (€)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-5 USD ($)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-5 Former Operating Company USD ($)	Mar. 29, 2011 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-5 Former Operating Company EUR (€)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-6 USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-6 Maximum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-6 Maximum EUR (€)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Clinical Study Nordic Series A-6 Minimum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-TD Phase 2 Clinical Study Nordic Series A-6 USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-TD Phase 2 Clinical Study Nordic Series A-6 Minimum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Extension Clinical Study Nordic Series A-6 USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Extension Clinical Study Nordic Series A-6 Maximum USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Extension Clinical Study Nordic Series A-6 Maximum EUR (€)	Jun. 30, 2013 Clinical Trial Services Agreement Stock Issuance Agreement BA058-SC Phase 3 Extension Clinical Study Nordic Series A-6 Minimum USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Letter of Intent BA058-SC Phase 3 Extension Clinical Study Nordic USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Letter of Intent BA058-SC Phase 3 Extension Clinical Study Nordic EUR (€)
Research Agreements
Number of countries where study was to be conducted																	10																		12
Number of additional countries where study will be conducted																												2
Number of additional study sites																													5			15
Final payments, number of euro-denominated installments					2	2
Final payments, number of U.S dollar-denominated installments					2	2
Amount of euro-denominated payments required over the course of Clinical Study					$ 53,500,000	€ 41,200,000			$ 4,700,000	€ 3,600,000																$ 5,900,000	€ 4,500,000			$ 1,600,000	€ 1,200,000		$ 933,728	€ 717,700				$ 4,800,000	€ 3,700,000
Amount of U.S. dollar-denominated payments required over the course of Clinical Study					3,200,000				257,853																	579,495				143,369			289,663					205,540
Value of shares agreed to be purchased																																										371,864
Purchase price per share of convertible preferred stock (in dollars per share)																																									$ 8.142					$ 8.142		$ 8.142				$ 8.142
Shares sold																																									64,430
Proceeds from issuance of shares																																								525,154
Number of shares exchanged in the Merger																																									6,443
Aggregate value of quarterly stock dividends, payable in shares											2,900,000																																	47,900,000	36,800,000
Aggregate euro denominated value of quarterly stock dividends, payable in shares																																																		5,900,000	4,500,000
Aggregate U.S. dollar value of quarterly stock dividends, payable in shares																																																		300,000
Number of shares due to the counter party																																											373,694				25,772		12,886
Number of shares due to the counter party after conversion of stock																																											3,736,940				257,720		128,860
Fair value of liability																																											16,500,000				1,100,000		600,000
Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash							11,400,000	800,000				400,000
Assets reflected in prepaid expenses and other current assets resulting from services which are payable in the form of a stock dividend																																																	30,000
Amounts reflected in accrued expenses and other current liabilities resulting from services payable in stock																																											3,200,000				200,000
Amount of initial payments for Euro-denominated installments																																																					1,100,000	806,468
Period for which research and development expense is recognized																				20 months			9 months		9 months
Research and development expense	16,240,000	14,499,000	33,527,000	24,366,000									900,000	3,600,000	2,000,000	4,900,000		8,800,000	6,900,000	17,900,000	11,800,000	1,700,000	3,400,000	800,000	1,300,000
Reduction in amount of euro-denominated payments required over the course of clinical study																																				$ 15,535	€ 11,941